+

WO2017018791A1 - Extrait de fruit de ginseng contenant un ingrédient fonctionnel préventif contre les dommages hépatiques dus à l'alcool et procédé de préparation de celui-ci - Google Patents

Extrait de fruit de ginseng contenant un ingrédient fonctionnel préventif contre les dommages hépatiques dus à l'alcool et procédé de préparation de celui-ci Download PDF

Info

Publication number
WO2017018791A1
WO2017018791A1 PCT/KR2016/008180 KR2016008180W WO2017018791A1 WO 2017018791 A1 WO2017018791 A1 WO 2017018791A1 KR 2016008180 W KR2016008180 W KR 2016008180W WO 2017018791 A1 WO2017018791 A1 WO 2017018791A1
Authority
WO
WIPO (PCT)
Prior art keywords
ginseng
ginseng fruit
ethanol
enzyme
group
Prior art date
Application number
PCT/KR2016/008180
Other languages
English (en)
Korean (ko)
Inventor
이대영
김금숙
이승은
이영섭
지승헌
안영섭
문원국
문지성
오지영
김성웅
유주연
이예진
Original Assignee
주식회사 네추럴에프앤피
대한민국(농촌진흥청장)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020150105726A external-priority patent/KR20170012981A/ko
Application filed by 주식회사 네추럴에프앤피, 대한민국(농촌진흥청장) filed Critical 주식회사 네추럴에프앤피
Publication of WO2017018791A1 publication Critical patent/WO2017018791A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/06—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)

Definitions

  • An object of the present invention relates to a method for extracting an extract comprising a functional ingredient for preventing alcoholic liver damage from ginseng fruit.
  • Korea's ginseng has a historical record of about 1,000 years ago, and is currently a global market scale of about $ 3.5 billion, making it a unique traditional Chinese medicine or health functional food for domestic venture companies to enter the world market.
  • Ginseng is a perennial semi-negative plant belonging to Ogapiaceae, and its efficacy is widely used in various documents in China and Korea, and it has been used as a herbal medicine in many fields since ancient times.
  • the components of ginseng are carbohydrates (60-70%), nitrogen-containing compounds. (12-16%), saponins (3-6%), fat-soluble ingredients (1-2%), ash (4-6%), vitamins (0.005%), and more.
  • Ginseng has been widely studied in modern times, ginseng is known to contain a large amount of ginsenoside (Ginsenoside), and in addition to the medicinal herbs used in the past, it is recently applied to foods and used a lot as a health food material. Ginseng usually takes more than 4 years to grow, and to get the best quality ginseng, it must be grown for 6 years. There is a disadvantage that the price is expensive, and it takes a long time to get ginseng.
  • Ginseng begins to bloom in ginseng for more than three years, and green fruits appear in May. By mid-July, the green fruits of ginseng will ripen and turn red.
  • the roots of ginseng are mainly used, and when the ginseng fruit is started to promote root growth rather than reproductive growth, the ginseng fruit is picked up.
  • ginsenoside Re is much higher in ginseng fruit than ginseng root, and it is known to have central nervous system inhibitory effect, DNA and RNA promotion, prasmin activation, and adrenal cortex stimulating hormone secretion.
  • Rb 2 is known to have a central nervous system, DNA and RNA synthesis, plasmin activation, corticosteroid secretion, and antidiabetic activity.
  • Ginsenoside means saponin in ginseng, and ginseng contains various kinds of ginsenosides. Ginsenosides of ginseng include panaxadiol (PD), panaxatriol (PT), and oleane (Oleanane). In addition to the ginsenoside component, ginseng includes carbohydrates such as starch, antioxidant aromatic compounds of polyacetylene, gomisin (Gomisin N-A) for protecting the liver, and acid peptides having a similar insulin action.
  • PD panaxadiol
  • PT panaxatriol
  • Ole oleane
  • ginseng includes carbohydrates such as starch, antioxidant aromatic compounds of polyacetylene, gomisin (Gomisin N-A) for protecting the liver, and acid peptides having a similar insulin action.
  • ginsenosides The main pharmacological action of ginsenosides, including the central nervous system, affects the endocrine system, immune system, metabolic system, etc., and has various effects on body control functions.
  • ginsenoside has a high lipolysis ability, promotes nutrient absorption and digestion, and promotes metabolism and energy by activating intracellular enzymes, thereby improving energy recovery, fatigue, powerlessness, anorexia, and serum protein synthesis. It is known that there is an effect such as acceleration.
  • the present invention is to solve the above problems, an object of the present invention is to provide a method for efficiently producing a ginseng fruit extract, more specifically by extracting the extract from ginseng fruit, the total content of ginsenosides is increased An object of the present invention is to provide a high quality ginseng fruit extract and extraction method.
  • an object of the present invention is to provide a ginseng fruit extract having a liver cell protective effect against alcohol and a method of preparing the same.
  • the present invention is a method for extracting ginseng fruit extract containing a functional ingredient for preventing alcoholic liver damage, a) freezing drying the ginseng fruit to prepare a ginseng fruit frozen crushed liquid and b) the ginseng Adding enzyme to the fruit lysate crushed solution and c) extracting the enzyme-reacted mixture using alcohol.
  • the ginseng fruit is characterized in that the lyophilized fruit pulverized by removing the seeds by lyophilization for 3 days at -25 ⁇ -35 °C to prepare a frozen crushing liquid.
  • the enzyme used in the enzyme reaction includes at least one enzyme selected from the group consisting of pectinase, cellulase, and hemi-cellulase among enzymes capable of hydrolyzing Pectin and cellulose It is done.
  • the pectinase is characterized in that it comprises the step of reacting the enzyme containing more than 80000u / g.
  • the enzyme is characterized in that it comprises the step of enzymatic reaction under the conditions of pH 3.0 ⁇ 5.0 at a temperature of 40 ⁇ 65 °C.
  • the alcohol extraction step is characterized in that it comprises the step of extracting the mixture of the enzyme reaction while maintaining a temperature of 45 ⁇ 55 °C.
  • the method for preparing ginseng fruit extract according to the present invention can improve the yield of ginsenosides obtained from ginseng fruit by freeze-drying the ginseng fruit as a raw material, and extract using alcohol after the hydrolase reaction.
  • the yield and antioxidant capacity of ginsenosides By improving the yield and antioxidant capacity of ginsenosides, the effect of preventing damage to liver cells can be enhanced, which can provide a higher quality product than products without steaming or treating enzymes. It has advantages.
  • Figure 1 shows the ginseng fruit extraction pilot production process
  • the production yield of the pilot scale for the raw material shows that the higher the amount of enzyme addition to 3.5 ⁇ 4.8%.
  • FIG. 2 shows the changes in the liver enzymes (ALT, AST) according to the ginseng fruit treatment in HepG2 cells induced by alcoholic liver toxicity.
  • Figure 3 (A) is a graph showing the results of the MTT assay for the bark tree sample, (B) MTT assay results for ginseng fruit-A, (C) MTT assay results for ginseng fruit-B, respectively It is shown in the graph.
  • FIG. 4 is a graph showing the results of inducing liver toxicity by ethanol administration by specifying blood levels of GOT / AST, GPT / ALT and LDH, which are indicators of liver toxicity.
  • Figure 5 shows the levels of blood GOT / AST and GPT / ALT in a bar graph respectively.
  • Figure 6 shows the bar graph showing the blood concentration of LDH by the bark extract, Ginseng Berry-A and Ginseng Berry-B for alcoholic liver disease.
  • Figure 7 shows the bar graph of the weight of liver and spleen by the ethanol administration after the administration or pretreatment of the bark extract, Ginseng Berry-A and Ginseng Berry-B.
  • Figure 8 shows the bar graph of the weight gain rate by the ethanol administration after the administration or pretreatment of the bark extract, Ginseng Berry-A and Ginseng Berry-B.
  • Figure 9 is a bar graph showing the measurement of the expression of antioxidant activity-related enzymes SOD (Superoxide dismutase) and catalase (catalase).
  • 10 is a Western blot of the expression group of the inflammation-related molecules COX-2, HO-1, iNOS and TGF- ⁇ 1 and the group administered with the bark extract, Ginseng Berry-A and Ginseng Berry-B and the group after the pretreatment ( Western blot) results.
  • Figure 11 shows the bar graph by measuring the change in blood liver levels according to the administration of the bark extract, Ginseng Berry-A and Ginseng Berry-B.
  • Figure 12 is an anatomical observation of the liver tissue of the mice administered the larvae extract, Ginseng Berry-A and Ginseng Berry-B.
  • Figure 13 is an anatomical observation of liver tissues treated with ethanol after the larvae extract, Ginseng Berry-A and Ginseng Berry-B.
  • the ginseng fruit may include an alcoholic liver damage prevention functional ingredient, characterized in that the fruit pulp crushed to remove the seeds freeze-dried at -25 ⁇ -35 for 3 days to prepare a frozen crushed liquid.
  • the enzyme is an alcoholic liver damage prevention functional component comprising at least one enzyme selected from the group consisting of pectinase, cellulase and hemi-cellulase among enzymes capable of hydrolyzing pectin and cellulose Ginseng fruit extract containing can be prepared.
  • the step of obtaining the enzyme-reacted mixture, the ginseng fruit extract comprising an alcoholic liver damage prevention functional component may be prepared, including the step of reacting the enzyme containing the pectinase 80000u / g or more.
  • the step of obtaining a mixture of the enzyme reaction, to prepare a ginseng fruit extract containing an alcoholic liver damage prevention functional component comprising the step of enzymatically reacting the enzyme at a temperature of pH 3.0 ⁇ 5.0 at a temperature of 40 ⁇ 65 °C Can be.
  • the extracting step may include the step of extracting the ginseng fruit extract while maintaining a temperature of 45 ⁇ 55 °C to prepare a ginseng fruit extract containing an alcoholic liver damage prevention functional component.
  • An embodiment of the present invention may include a ginseng fruit extract prepared by the method described above.
  • embodiments of the present invention may include a liver damage prevention functional dietary supplement comprising the extract prepared by the method described above.
  • the freeze-drying of the ginseng fruit is preferably performed so that the moisture of the ginseng fruit is 4.55% for 3 days.
  • the present inventors prepared freeze-dried crushed ginseng fruit lysate to increase the content of ginsenosides by using the characteristics that the lyophilized products have good crushability and minimize material changes such as nutrients of the raw materials.
  • Ginseng fruits DPPH radical scavenging IC 50 of its own pulp as indicated in Table 1 was shown to 449.3ppm, by maintaining the temperature at 50 °C the IC 50 value from the results confirmed that change according to the time 3 hours treatment lowest 321.12 It was found to be ppm, and then increased to 342.91ppm in 5 hours.
  • the IC 50 value tended to decrease as the extraction time increased, unlike the control group. In this case, when extracting the frozen ginseng fruit crushed liquid, it can be predicted that increasing the extraction time to increase the content of the antioxidant component.
  • the enzyme extraction conditions were selected using the following method for efficient extraction of alcoholic liver damage prevention functional components of ginseng fruit. After adding 100% (v / v) of warm purified water to 1kg of ginseng berry frozen crushing solution, adding 0.05 and 0.2% of enzymes, respectively, and hydrolyzing them at 50 °C reflux water bath for 3 and 5 hours to filter the nonwoven fabric. The filtrate was lyophilized and used as analytical sample. The results of investigating the antioxidant properties according to pectin and cellulose hydrolase treatment are shown in Table 2 below.
  • Enzyme Type Enzyme Concentration (%) Enzyme Processing Time (hr)
  • the DPPH radical scavenging activity IC 50 (ppm) Control 0 0 0 449.3 Control group 3 0 3 321.12 Control group 5 0 5 342.91 Enzyme A 0.05 3 314.3 5 381.5 0.2 3 329.3 5 377.6 Enzyme B 0.05 3 359.3 5 345.4 0.2 3 386.2 5 428.7
  • Enzyme A of Table 2 is Sumizyme SPC, which is a combination of pectinase, cellulase and hemi-cellulase among enzymes capable of hydrolyzing pectin and cellulose, and particularly, containing 80000 u / g or more of pectinase.
  • 1u means the amount of enzyme capable of producing 1 ⁇ mol galacturonic acid per minute by decomposing the polygalacturonic acid under the conditions of pH 4.0 and 25 ° C. by the sigma method.
  • the enzyme reaction is treated under the conditions of pH 3.0 to 5.0 at a temperature of 40 to 65 °C.
  • Enzyme B of Table 2 is a plantase TCL, which is a combination of pectinase and cellulase among enzymes capable of hydrolyzing pectin and cellulose, in particular, 190u / g pectinase and 1495U / g or more cellulase It is characterized by including.
  • 1U refers to the amount of enzyme capable of producing 1 ⁇ mol of glucose per minute by decomposing the substrate carboxymethyl cellulose.
  • the enzyme reaction is treated at a pH of 2.0 to 5.5 at a temperature of 40 to 60 °C.
  • the ginsenoside content was extracted by using enzymes and spirits which can be used as foods for ginseng fruit for efficient total ginsenoside extraction, and the results are shown in Table 3 below.
  • Table 3 shows the ginsenoside component changes according to ginseng fruit hydrolysis and alcohol extraction. Looking at the Table 3, the content of Rg 1 was the highest overall, followed by Re, Rd, Rb 2 , F3, Rc, F2, F5, Rb 1 , Rg 2 , F 1 , Rf, Rb 3 , Rh 1 High. The total ginsenoside content was the highest at 9.58% when extracted for 3 hours in the control group, and 10.82 ⁇ 10.84% for 3 hours and 5 hours in the alcohol extract group. In the enzyme treatment section, enzyme A, 0.2%, and 14.39% in 3 hours were the highest, and enzyme B, 11.31% in 5 hours.
  • Example 4 As a result of Example 4, the lowest IC 50 value for DPPH radical was found in enzyme A, and the total content of ginsenoside was detected to be the highest, thereby hydrolyzing the ginseng fruit using enzyme A. After treatment, it can be predicted that alcohol extraction will increase the total ginsenoside content.
  • the minimum test production scale extraction process was performed as shown in FIG. 1 by varying the concentration of enzyme A selected in the previous study. Unlike in the laboratory, this process adds enzyme deactivation, concentration, and sterilization processes, which are necessary for quality control when proceeding to production and products, and spray drying was performed to reduce production costs.
  • Figure 1 shows the ginseng fruit extraction minimum test production scale production process.
  • the yield of the minimum test production scale for this raw material was 3.5-4.8%, indicating that the higher the amount of enzyme addition, the higher the yield was.
  • FIG. 2 shows the changes in the liver enzymes (ALT, AST) according to the ginseng fruit treatment in HepG2 cells induced by alcoholic liver toxicity.
  • in vitro hepatotoxicity can be confirmed by measuring the amount of transaminase released in the culture medium of the cells, ALT (Alanine) into the cells after 24 hours of ethanol treatment to liver cells such as HepG2 transaminase) and AST (aspartate transaminase) release.
  • ALT Alanine
  • AST aspartate transaminase
  • ginseng fruit-A ginseng fruit extract prepared by using enzyme A
  • ginseng fruit-B ginseng fruit extract prepared by using enzyme B
  • Cytotoxicity was measured by diluting the bark, Ginseng-A and Ginseng-B samples at various concentrations and incubating for 48 hours, followed by MTT assay.
  • Figure 3 (A) is a graph showing the results of the MTT assay for the bark tree sample, (B) MTT assay results for ginseng fruit-A, (C) MTT assay results for ginseng fruit-B, respectively It is shown in the graph.
  • the horizontal axis represents dose ( ⁇ g / ml) and the vertical axis represents cell growth rate (%).
  • mice Five-week-old male Balb / c mice were orally administered with 25% ethanol once a day for a total of 7 days at a dose of 5 g / kg to induce alcoholic liver disease.
  • FIG. 4 is a graph showing the results of inducing liver toxicity by ethanol administration by specifying blood levels of GOT / AST, GPT / ALT and LDH, which are indicators of liver toxicity.
  • Figure 4 (A) is a graph showing the blood concentration of GOT / AST (U / I), (B) is a graph representing the blood concentration of GPT / ALT (U / I), (C) is LDH ( U / I) is a graph indicating the blood concentration.
  • liver cells are damaged and toxicity is expressed.
  • GOT / AST and GPT / ALT in serum of mice administered orally at a rate of 0.5 mg / mouse and 1 mg / mouse once a day for 3 days before ethanol administration Quantification confirmed the liver disease inhibitory activity of the sample.
  • serum GPT / ALT, GOT / AST, and LDH were quantified using serum samples on the first day after ethanol administration was completed.
  • Figure 5 shows the levels of blood GOT / AST and GPT / ALT in a bar graph respectively.
  • Statistical significance was examined by Student's two tailed t-test for the ethanol-only group, where * means p ⁇ 0.05.
  • liver disease is damaged when liver disease occurs, and the blood concentration of LDH enzymes present in liver cells is increased by the use of alcoholic extracts of barberry, ginseng fruit-A and ginseng for liver disease.
  • the effect of inhibiting liver damage of fruit-B was observed.
  • Figure 6 shows the bar graph showing the blood concentration of LDH by the bark extract, Ginseng Berry-A and Ginseng Berry-B for alcoholic liver disease.
  • the horizontal axis in order from the left side to the group not administered ethanol (NONE), ethanol only group (EtOH only), ethanol and hut tree extract 0.5mg together, ethanol and hut tree extract 1mg Group administered together, ethanol and ginseng fruit-A 0.5mg group, ethanol and ginseng fruit-A 1mg group, ethanol and ginseng fruit-B 0.5mg group, ethanol and ginseng Fruit-B 1mg was administered together, the vertical axis represents the blood LDH (U / I). Statistical significance was examined by Student's two tailed t-test for the ethanol-only group, where * means p ⁇ 0.05 and ** means p ⁇ 0.01. do.
  • the barberry extract, ginseng fruit-A and ginseng fruit-B group And the weight of liver and spleen of the ethanol-administered group after pretreatment of the sample was measured.
  • Figure 7 shows the bar graph of the weight of liver and spleen by the ethanol administration after the administration or pretreatment of the bark extract, Ginseng Berry-A and Ginseng Berry-B.
  • Figure 7 (C) the horizontal axis in order from the left in the group not administered ethanol (NONE), the ethanol only group (EtOH only), the group administered with 0.5 mg of the locust tree, the ethanol extract 1mg administered Group, the group administered ginseng-A 0.5mg, the group administered ginseng-A 1mg, the group administered ginseng-B 0.5mg, the group administered the ginseng-B 1mg, the vertical axis represents the spleen ( spleen) weight in grams.
  • the horizontal axis is sequentially administered from the left side to the group not administered ethanol (NONE), the group administered only ethanol (EtOH only), the group administered with 0.5 mg of holly tree extract, and the holly tree extract 1 mg.
  • the vertical axis means the weight increase rate (% increase rate).
  • SOD Superoxide dismutase
  • catalase enzymes related to antioxidant activity in liver tissues
  • Figure 9 is a bar graph showing the measurement of the expression of antioxidant activity-related enzymes SOD (Superoxide dismutase) and catalase (catalase).
  • SOD Superoxide dismutase
  • Catalase catalase
  • FIG 9 (A) the horizontal axis from the left in order from the group not administered ethanol (NONE), ethanol-only group (EtOH only), ethanol and hut tree with 0.5mg, ethanol and hut tree Group administered with 1mg of extract, group administered with 0.5mg of ethanol and ginseng-A, group administered with ethanol and ginseng-A 1mg together, group administered with 0.5mg of ethanol and ginseng-A, ethanol And ginseng fruit-B 1mg was administered together, and the vertical axis represents the expression level (U / ml) of SOD (Superoxide dismutase).
  • FIG. 9 (B) the horizontal axis in order from the left in the group not administered ethanol (NONE), ethanol-only group (EtOH only), ethanol and hut tree extract 0.5mg group, ethanol and hut tree Group administered with 1mg of extract, group administered with 0.5mg of ethanol and ginseng-A, group administered with ethanol and ginseng-A 1mg together, group administered with 0.5mg of ethanol and ginseng-A, ethanol And ginseng berry-B 1mg were administered together, and the vertical axis represents the expression amount (U / ml) of catalase.
  • Statistical significance was examined by Student's two tailed t-test for the ethanol-only group, where * means p ⁇ 0.05 and ** means p ⁇ 0.01. do.
  • Ginseng Berry-A and Ginseng Berry-B and inflammation related factors such as COX-2, iNOS, HO-1, TGF- ⁇ 1 in liver cells
  • COX-2, iNOS, HO-1, TGF- ⁇ 1 in liver cells The expression levels of the COX-2, iNOS, HO-1, and TGF- ⁇ 1 in the A- and ginseng-B group and the ethanol-treated group after pretreatment were measured by Western blot.
  • 10 is a Western blot of the expression group of the inflammation-related molecules COX-2, HO-1, iNOS and TGF- ⁇ 1 and the group administered with the bark extract, Ginseng Berry-A and Ginseng Berry-B and the group after the pretreatment ( Western blot) results.
  • Ginseng Berry-A and Ginseng Berry-B changes in blood liver levels were measured according to the administration of the Barberry extract, Ginseng Berry-A and Ginseng Berry-B.
  • the horizontal axis is the group administered with nothing from the left (NONE), the group administered with ethanol only (EtOH only), the group administered with 0.5 mg of hawthorn, and the group administered with 1 mg of hawthorn , Ginseng Berry-A 0.5mg group, Ginseng Berry-A 1mg group, Ginseng Fruit-B 0.5mg group, Ginseng Fruit-B 1mg group, the vertical axis represents GOT / AST The concentration of (U / I) is shown.
  • the horizontal axis is the group administered nothing (NONE), the ethanol-only group (EtOH only), the group administered with 0.5 mg of the locust extract, the group administered the 1 mg of the locust extract in order from the left , Ginseng Fruit-A 0.5mg group, Ginseng Fruit-A 1mg group, Ginseng Fruit-B 0.5mg group, Ginseng Fruit-B 1mg group, the vertical axis is GPT / ALT The concentration of (U / I) is shown.
  • Figure 13 is an anatomical observation of liver tissues treated with ethanol after the larvae extract, Ginseng Berry-A and Ginseng Berry-B. As a result of observation according to FIG. 13, no significant liver damage was observed in the ethanol-administered group, and thus the reading was difficult. However, no damage to liver tissue was observed in the mice pretreated with the bark extract, Ginseng Berry-A and Ginseng Berry-B. I could confirm it.
  • the present invention includes a dietary supplement comprising ginseng fruit extract rich in ginsenosides prepared by the above-mentioned method and high in liver cell protection, wherein the dietary supplement is a liquid beverage formulation.
  • the dietary supplement is a liquid beverage formulation.
  • the extract of ginseng fruit may be powdered using a method such as spray drying, and the powder may be provided in any one or more solid dosage forms selected from tablets, pills, powders, tablets, and capsules. have.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne un procédé permettant de préparer, à partir de fruit de ginseng, un extrait contenant un ingrédient fonctionnel préventif contre les dommages hépatiques dus à l'alcool et, spécifiquement, un procédé de préparation d'un extrait de fruit de ginseng de haute qualité ayant à la fois une quantité totale de ginsénoside plus élevée et un effet protecteur des cellules hépatiques contre l'alcool. Le procédé consiste à soumettre un broyat congelé de fruit de ginseng, qui a été préparé à partir de pulpe de fruit de ginseng lyophilisée, à une réaction enzymatique utilisant au moins une hydrolase choisie dans le groupe constitué de pectinase, de cellulase et d'hémicellulase, et à extraire celui-ci par un procédé d'extraction à l'éthanol tout en maintenant la température entre 45 et 55 °C.
PCT/KR2016/008180 2015-07-27 2016-07-27 Extrait de fruit de ginseng contenant un ingrédient fonctionnel préventif contre les dommages hépatiques dus à l'alcool et procédé de préparation de celui-ci WO2017018791A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2015-0105726 2015-07-27
KR1020150105726A KR20170012981A (ko) 2015-07-27 2015-07-27 알코올성 간 손상 예방 기능성 성분을 포함하는 인삼열매 추출물 및 그 제조 방법
KR10-2016-0093761 2016-07-22
KR1020160093761A KR102005031B1 (ko) 2015-07-27 2016-07-22 알코올성 간 손상 예방 기능성 성분을 포함하는 인삼열매 추출물 및 그 제조 방법

Publications (1)

Publication Number Publication Date
WO2017018791A1 true WO2017018791A1 (fr) 2017-02-02

Family

ID=57884771

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/008180 WO2017018791A1 (fr) 2015-07-27 2016-07-27 Extrait de fruit de ginseng contenant un ingrédient fonctionnel préventif contre les dommages hépatiques dus à l'alcool et procédé de préparation de celui-ci

Country Status (2)

Country Link
KR (1) KR102005031B1 (fr)
WO (1) WO2017018791A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023020290A1 (fr) * 2021-08-16 2023-02-23 合肥工业大学 Polypeptide dérivé de jambon sec et apte à atténuer des lésions hépatiques alcooliques, et son procédé de préparation

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101977608B1 (ko) * 2017-12-19 2019-05-13 강릉원주대학교 산학협력단 신규 비알코올성 지방간질환 치료용 조성물
KR102204912B1 (ko) * 2019-03-08 2021-01-19 주식회사 한국인삼공사 인삼 추출물의 분획물을 포함하는 간질환 예방 또는 치료용 약학적 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110078525A (ko) * 2009-12-31 2011-07-07 (주)아모레퍼시픽 인삼 열매 추출물을 함유하는 간기능 개선용 조성물
KR101051519B1 (ko) * 2010-12-21 2011-07-22 한국인삼열매공사 주식회사 인삼 열매 추출물 제조 방법
WO2014178474A1 (fr) * 2013-04-30 2014-11-06 재단법인 금산국제인삼약초연구소 Procédé de production d'un extrait de baies de ginseng à teneur renforcée en ginsénosides re
KR20150051811A (ko) * 2013-11-05 2015-05-13 재단법인 홍천메디칼허브연구소 홍삼추출물 및 인삼 열매 추출물을 포함하는 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110078525A (ko) * 2009-12-31 2011-07-07 (주)아모레퍼시픽 인삼 열매 추출물을 함유하는 간기능 개선용 조성물
KR101051519B1 (ko) * 2010-12-21 2011-07-22 한국인삼열매공사 주식회사 인삼 열매 추출물 제조 방법
WO2014178474A1 (fr) * 2013-04-30 2014-11-06 재단법인 금산국제인삼약초연구소 Procédé de production d'un extrait de baies de ginseng à teneur renforcée en ginsénosides re
KR20150051811A (ko) * 2013-11-05 2015-05-13 재단법인 홍천메디칼허브연구소 홍삼추출물 및 인삼 열매 추출물을 포함하는 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIM, SEUNG TAE ET AL.: "Establishment of Optimal Fermentation Conditions for Steam-dried Ginseng Berry via Friendly Bacteria and Its Antioxidant Activities", KOREAN JOURNAL OF FOOD SCIENCE AND TECHNOLOGY, vol. 45, no. 1, 2013, pages 77 - 83, XP053031448 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023020290A1 (fr) * 2021-08-16 2023-02-23 合肥工业大学 Polypeptide dérivé de jambon sec et apte à atténuer des lésions hépatiques alcooliques, et son procédé de préparation

Also Published As

Publication number Publication date
KR102005031B1 (ko) 2019-07-31
KR20170013170A (ko) 2017-02-06

Similar Documents

Publication Publication Date Title
Ye et al. Anoectochilus roxburghii: A review of its phytochemistry, pharmacology, and clinical applications
CA2480438C (fr) Nouvelle utilisation de l'extrait de ginseng traite et saponine isolee a partir de ce dernier
WO2017104966A1 (fr) Composition contenant des saponines de panax ginseng comme principe actif
Hao-Cong et al. Chemical constituents and pharmacologic actions of Cynomorium plants
WO2015002391A1 (fr) Composition présentant une fonction d'atténuation du syndrome prémenstruel et des douleurs menstruelles
WO2018174589A1 (fr) PROCÉDÉ POUR SOULAGER LA GINGIVITE ET LA PARODONTITE PAR ANTIBIOSE, ANTIOXYDATION, ANTI-INFLAMMATION, SUPPRESSION DE LA PERTE OSSEUSE PARODONTALE ET RÉGÉNÉRATION DE L'OS PARODONTAL AU MOYEN D'UN COMPLEXE D'EXTRAIT DE FEUILLE DE MORINGA OLEIFERA ET D'EXTRAIT D'EUCOMMIA ULMOIDES <i /><i />
WO2010137846A2 (fr) Composition pour accroître de la biodisponibilité de la saponine
WO2016182225A1 (fr) Composition de prévention de la chute des cheveux et de stimulation de la croissance des cheveux
WO2019190161A1 (fr) Composition à base de ginseng entier utilisant des racines, des feuilles et des baies de ginseng et son procédé de préparation
WO2017018791A1 (fr) Extrait de fruit de ginseng contenant un ingrédient fonctionnel préventif contre les dommages hépatiques dus à l'alcool et procédé de préparation de celui-ci
WO2007007993A1 (fr) Composition pharmaceutique destinee a la prevention et au traitement de maladies du foie contenant un extrait de lonicera caerulea l. var. edulis
KR102209028B1 (ko) 증포 인삼열매 발효물을 유효성분으로 포함하는 퇴행성 뇌질환 예방 또는 치료용 약학적 조성물
KR100483707B1 (ko) 관절 보호용 생약조성물
WO2016080691A1 (fr) Composition pharmaceutique comprenant des extraits de symplococs chinesis et astragalus membranaceus pour prévenir et traiter l'arthrite, et son procédé de préparation
WO2019182318A9 (fr) Procédé de préparation de composé k à l'aide de germes de ginseng, et composition antioxydante et antibactérienne contenant le composé k préparé selon le procédé
WO2022010035A1 (fr) Composition pharmaceutique anticancéreuse comprenant un extrait de plantes
WO2016159524A2 (fr) Composition pour atténuer le vieillissement ovarien contenant un extrait de baie de ginseng
WO2016076607A2 (fr) Composition pharmaceutique et aliment fonctionnel pour la santé, contenant un concentré de ginseng rouge avec un composé enrichi en composant k, pour la prévention et le traitement du symptôme de la stéatose hépatique d'origine non alcoolique
WO2016190566A9 (fr) Composition pharmaceutique ou aliment naturel fonctionnel pour la prévention et le traitement de maladies métaboliques, contenant un extrait aqueux de pleurotus eryngii var. ferulae (pf.) en tant que principe actif
WO2019050123A1 (fr) Composition alimentaire pour traiter l'obésité ou l'hyperlipidémie comprenant un extrait de fruit de terminalia chebula et un extrait de phyllanthus emblica
WO2010095808A2 (fr) Procédé de production d'extrait d'astragalus membranaceus par enzymolyse, et composition pour prévenir ou soulager le diabète ou l'obésité, contenant un principe actif comprenant un extrait d'astragalus membranaceus produit à l'aide dudit procédé de production
KR20100048593A (ko) 인삼 사포닌의 장내 세균 대사 억제용 조성물
WO2018008973A1 (fr) Composition comprenant un extrait de forsythiae fructus en tant que principe efficace pour prévenir, améliorer ou traiter la neuropathie périphérique
CN103070893A (zh) 马齿苋制备治疗老年性痴呆的药物
CN113082085A (zh) 一种管花肉苁蓉提取物及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16830824

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16830824

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载